Intravenous therapy | Medical XPRT
Articles & Whitepapers
-
Development of a Novel Encapsulated Non-Viral Cell- Based, BBB-Penetrant Therapy for MPS I
Introduction MPS I is caused by a deficiency of the lysosomal enzyme a-L-iduronidase (IDUA) leading to GAG accumulation in multiple tissues and organs This accumulation results in a complex array of progressive, multi-systemic pathologies, including CNS manifestations Approved therapies include enzyme replacement therapy (ERT), with chaperone and gene therapies under investigation Treatment ...
-
Development of a Novel Encapsulated Non-Viral Cell-Based, BBB-Penetrant Therapy for MPS I
MPS I is caused by deficiency of the lysosomal enzyme a-L-iduronidase (IDUA) leading to GAG accumulation in multiple tissues and organs This accumulation results in a complex array of progressive, ...
News
-
Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SeValent
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for ...
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
Deborah Heart and Lung Center Introduces the Ivenix Infusion System to the Hospital
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease
Equipment & Solutions
-
Showcase
Administration Sets
Low cost gravity IV administration set. All sets feature Non-DEHP fluid paths, including tubing and drip chamber. Latex Free. Available with .22 micron in-line filter. Available with needleless access connector. Wide selection of sets and components to meet a variety of solution administration requirements.